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Abstract
Background: Regulation of gene expression is essential for normal development and cellular
growth. Transcriptional events are tightly controlled both spatially and temporally by specific DNA-
protein interactions. In this study we finely map the genome-wide targets of the CREB protein
across all known and predicted human promoters, and characterize the functional consequences
of a subset of these binding events using high-throughput reporter assays. To measure CREB
binding, we used HaloCHIP, an antibody-free alternative to the ChIP method that utilizes the
HaloTag fusion protein, and also high-throughput promoter-luciferase reporter assays, which
provide rapid and quantitative screening of promoters for transcriptional activation or repression
in living cells.
Results: In analysis of CREB genome-wide binding events using a comprehensive DNA microarray
of human promoters, we observe for the first time that CREB has a strong preference for binding
at bidirectional promoters and unlike unidirectional promoters, these binding events often occur
downstream of transcription start sites. Comparison between HaloCHIP-chip and ChIP-chip data
reveal this to be true for both methodologies, indicating it is not a bias of the technology chosen.
Transcriptional data obtained from promoter-luciferase reporter arrays also show an
unprecedented, high level of activation of CREB-bound promoters in the presence of the co-
activator protein TORC1.
Conclusion: These data suggest for the first time that TORC1 provides directional information
when CREB is bound at bidirectional promoters and possible pausing of the CREB protein after
initial transcriptional activation. Also, this combined approach demonstrates the ability to more
broadly characterize CREB protein-DNA interactions wherein not only DNA binding sites are
discovered, but also the potential of the promoter sequence to respond to CREB is evaluated.
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Background
Control of gene expression and transcription in mamma-
lian cells is typically achieved through a multi-layered net-
work of protein signaling pathways containing multiple
checkpoints to ensure specificity or correct transmission
of external stimuli. Regulation of transcriptional activa-
tion or repression is crucial for proper development, cell
growth, and routine progression through the cell cycle.
There is a rapidly growing body of data describing DNA-
protein interactions on a genome-wide scale, aided by
availability of complete mammalian genome sequences
and also the coupling of chromatin immunoprecipitation
(ChIP) experiments [1-3] with DNA microarrays analysis
(ChIP-chip) [4-10] or ultra high-throughput sequencing
(ChIP-Seq) [11-16]. While genome-wide maps of DNA-
protein interactions are crucial to understanding global
transcriptional networks, understanding the functional
consequences of these binding events is equally impor-
tant. To expand existing approaches to study DNA-protein
interactions in living cells, we present two complementary
technologies: HaloCHIP, an antibody-free alternative
approach to ChIP, for mapping protein binding sites on
DNA, and high-throughput reporter assays to measure the
promoter activity associated with binding events.
The success of ChIP relies heavily on the success of the
immunoprecipitation step in the process, creating a need
for alternative approaches when the antibody against the
DNA binding protein is either not functional or available
for the ChIP assay [17-21]. Such alternative approaches
are derived from the standard ChIP method and include
the initial formaldehyde crosslinking of protein:DNA
complexes, yet typically differ in the use of protein fusion
tags, which allow for complexes to be isolated using either
an antibody against the tag [17,21] or direct capture on a
resin that interacts with the fusion tag [18-20]. The latter
is the basis for the HaloCHIP method, which utilizes the
HaloTag protein [19,20], a 33 kDa protein fusion tag, that
can be cloned N- or C-terminally to a DNA binding pro-
tein of interest[19,20] (Figure 1). In the HaloCHIP
method, the HaloTag fusion protein is expressed either
transiently or stably in mammalian cells and crosslinked
complexes can be directly captured from a cellular lysate
via covalent binding to a HaloTag-specific resin, termed
HaloLink [19,20] (Figure 1). The complete covalent link-
age established at this point allows for extensive washing
to remove non-specific protein and DNA, followed by
standard reversal of the crosslinks to release the DNA frag-
ments which were bound to the DNA binding protein
(Figure 1). Several controls for the HaloCHIP method are
possible to show that capture is specific in this process and
provide an excellent estimate of background (Figure 1).
Both the HaloCHIP and ChIP method yield information
about the location and timing of binding events on DNA,
but do not provide information as to the cellular response
or consequence of the given binding event. Currently,
mRNA and protein levels are measured to determine
whether or not a gene has been activated or repressed, but
a more direct measure of the transcription potential or
function of bound DNA sequences would be ideal. To
complement these approaches and also increase sensitiv-
ity, high-throughput reporter assays can be used (Cooper
et al. 2006). High-throughput reporter assays utilize a
384-well format that enable the functional measure of
thousands of endogenous human promoters. Each indi-
vidual promoter is fused to a luciferase reporter gene and
transiently delivered to living cells. Upon protein binding
to the promoter region, the luciferase reporter gene is acti-
vated and the degree of this activation can be quantita-
tively determined before and after a stimulus by
measuring the light output. This allows real-time moni-
toring of transcriptional activation or repression from the
promoter-reporter construct after stimulus of a pathway
or response to other cellular conditions.
To demonstrate the use of these approaches to further
understanding of DNA-protein interactions in living cells,
we chose to study the CREB transcription factor [22-25].
The model system of the CREB signaling pathway has
been elegantly studied and its binding targets have been
described previously at the level of individual promoters
as well as a genome-wide scale [12,22,26-29]. CREB
belongs to a family of transcription factors including acti-
vating transcription factor 1 (ATF1) and the cAMP
response element modulator (CREM), which regulate
gene expression in response to changes in cAMP and other
cellular signals [23,24]. Upon activation of the protein
kinase A pathway or stimulation of other kinases, CREB is
directly phosphorylated on several critical serines [22,30],
though phosphorylation is not required for binding to
DNA [31]. The phosphorylation events instead allow sub-
sequent recruitment and binding of transcriptional co-
activators CREB binding protein (CBP)/p300 as well as
transducers of regulated CREB (TORCs) to the promoter
region [32-35]. Previous studies have shown that CREB
co-factors are often necessary for transcription activation
and that CREB binding to DNA, even in its phosphor-
ylated form, is not usually sufficient to activate transcrip-
tion [34-39].
In this paper, CREB binding is mapped at a much higher
resolution than previous studies and covers all known and
predicted human promoters using the HaloCHIP method
in conjunction with DNA microarrays, ("HaloCHIP-
chip"). As this is a new approach for studying genome-
wide protein:DNA interactions, these data were compared
to the standard CREB ChIP-chip process using an anti-
body against the endogenous CREB protein, revealing a
high degree of overlap between the methods and also to
previously published data [26,29]. To further correlate
DNA binding events to potential transcription activationBMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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or repression, a subset of CREB-bound promoters were
analyzed using high-throughput reporter assays in the
presence or absence of protein kinase A pathway activa-
tors as well as the CREB transcriptional co-activator,
TORC1. All together these data reveal new CREB-bound
promoters and binding preferences on DNA, interesting
functional activities provided by the high-throughput
reporter assays, and new insights into CREB-mediated
transcription regulation.
Results
Specific binding and enrichment of CREB promoters in 
HaloCHIP
The significant advantages of the HaloCHIP method are
the direct and covalent capture of the crosslinked DNA-
Schematic of the HaloCHIP process Figure 1
Schematic of the HaloCHIP process. The HaloCHIP process is initiated by cloning a desired DNA binding protein-of-
interest, i.e. a transcription factor (TF) into a HaloTag (HT) fusion mammalian expression vector. For the experimental Halo-
CHIP sample, the HaloTag fusion protein is expressed in the desired cell line and then crosslinked to DNA in vivo with formal-
dehyde. Treated cells are lysed, sonicated to shear the chromatin, and incubated with HaloLink resin, which directly and 
covalently captures all crosslinked HaloTag-fusion complexes. The resin is stringently washed to remove non-specific proteins 
and DNA, and captured regions of DNA are released by reversal of the crosslinks. The resultant DNA can be further purified 
for downstream analysis. Two possible controls, which provide an estimate of background DNA capture, are recommended 
for the HaloCHIP process. The first, referred to in the text as the untransfected control, involves the use of untransfected cells 
which are processed in parallel with the HaloCHIP experimental sample. The second, referred to as the blocking ligand con-
trol, is generated by splitting the cell lysate equally into separate tubes prior to incubation with the HaloLink resin and incubat-
ing the control sample only with a fluorescent HaloCHIP blocking ligand, preventing interaction of the HaloTag complexes with 
the HaloLink resin during the subsequent incubation step.
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protein complexes on the HaloLink resin, eliminating the
need of an antibody and preventing loss or diffusion of
complexes after capture (Figure 1). As with the use of any
fusion tag, it is important to show the tagged protein
behaves similar to the endogenous protein. Previous stud-
ies with HaloTag fusion proteins have demonstrated
proper physiology, including DNA binding and localiza-
tion [19,40-45]. In order to demonstrate specific DNA
binding of the HaloTag-CREB fusion protein, HaloCHIP
assays were performed in triplicates using transiently
expressed HaloTag-CREB as the experimental sample and
untransfected HeLa cells as a control. The relative abun-
dance of three known CREB-specific promoters, Fos, Jun,
and p27, [24,28] and three negative control sequences,
called C1, C2, and C3, which are non-genic regions from
the human genome that lack CRE sites, were then ana-
lyzed using Plexor quantitative PCR (Figure 2). The CREB-
specific promoters show an average enrichment of 12.5
fold, while the untransfected control showed an enrich-
ment of 1.8 fold (Figure 2). The negative control
sequences are not enriched in either sample (Figure 2)
Similar results were obtained using the HaloCHIP block-
ing ligand (Figure 1) as a control (data not shown). After
this initial validation of specific binding, the HaloCHIP
DNA was then prepared for hybridization to a human
promoter microarray to ascertain binding on a genome-
wide scale.
HaloCHIP-chip DNA oligo array design
To measure the genome-wide binding sites of CREB and
to assess specificity of binding on a global scale, CREB
HaloCHIP DNA was hybridized to a custom DNA oligo
microarray. In the HaloCHIP-chip strategy, two samples,
the experimental and untransfected control, were each
treated with or without forskolin (FSK) and processed
through HaloCHIP (Figure 3). Similar to ChIP, the Halo-
CHIP derived DNA from each sample, typically 10-100
ng/reaction, required subsequent amplification to obtain
amounts sufficient (1-10 μg) for microarray analysis. The
whole genome amplification (WGA) method was used for
amplification [46], and the experimental and control
samples were labelled with Cy5 and Cy3, respectively
(Figure 3). A custom DNA oligo microarray was designed
based upon promoter regions defined by SwitchGear
Genomics genome-wide set of predicted transcription
start sites (Figure 3) [47-50]. An average of 14 probes,
each 50-mers, was designed to span a 1.8 kb region of
each known promoter region. The probes were chosen to
sequences primarily upstream of a transcription start site,
with an average of 131 bp spacing between probes. In
total, approximately 385,000 probes were used to cover
27,661 promoter regions, including 33,255 transcription
start sites (TSS) (Figure 3).
CREB HaloCHIP-chip array data analysis and cut-offs
A total of 7 independent CREB HaloCHIP-chip experi-
ments were conducted; 4 were treated with forskolin and
3 without. All showed significant enrichment, however
very few differences were detected between the untreated
and FSK treated samples, as was seen in previously pub-
lished data [29]. The log2 ratios obtained for each pro-
moter were averaged across the 7 independent array
experiments to obtain a single value for each promoter
region. To calculate the positive and negative predictive
values (PPV and NPV respectively) of the array data at dif-
ferent percentile thresholds, the promoters were sorted
based on their average log2 ratio for enrichment and vali-
dated by qPCR. For the PPV determination, 12 sequences
each were chosen from the Top 1%, 5%, and 10% of the
sorted list and for the NPV determination, 36 sequences
were randomly chosen from the bottom 50%. The Top
1%, 5%, and 10% categories showed PPVs of 100%, 92%,
and 50%, respectively (Table 1), while the NPV from the
Specific DNA binding of HaloTag-CREB in vivo Figure 2
Specific DNA binding of HaloTag-CREB in vivo. Halo-
CHIP experiments were performed in triplicates, on HeLa 
cells transiently expressing HaloTag-CREB or untransfected 
as a control. Resulting DNA from both the HaloTag-CREB 
and Untransfected control sample was amplified and analyzed 
using Plexor quantitative PCR. Total amounts of DNA for 
both samples were calculated for three promoters which 
CREB is known to bind [28], Fos, Jun, and p27, as well as 
three control sequences, C1, C2, and C3, which do not con-
tain CRE consensus binding sites. Depicted in dark blue is the 
fold enrichment of each CREB-specific promoter over the 
average amount of the three control promoters for the 
HaloTag-CREB HaloCHIP experimental sample. In light blue 
is the identical calculation for the Untransfected HaloCHIP 
control sample.
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Bottom 50% was calculated to be 94.5% (Table 1). These
values indicate the high quality of the data, and based
upon the PPV calculations, the cut-off for calling a pro-
moter "CREB-bound" in subsequent analyses was chosen
to be the Top 5% of the list, corresponding to 1,383 pro-
moters.
Comparison of CREB HaloCHIP-chip and ChIP-chip array 
data
To compare the binding of HaloTag-CREB to the physio-
logical expected binding pattern of the endogenous CREB
protein, a conventional ChIP-chip experiment using an
antibody to CREB in HeLa cells and using the same oligo
DNA microarray was performed. The Top 1% (277) and
Top 5% (1383) of promoters showed significant overlap,
35% and 45% respectively, between HaloCHIP and ChIP-
chip, representing a 44-fold and 10-fold over-representa-
tion of overlap compared to what would be predicted by
chance (Table 2). This degree of overlap is within the
range of similarity to what is seen between biological rep-
licates of either HaloCHIP-chip or ChIP-chip data sets,
indicating that the two methods are yielding equivalent
results within the limitations of experimental error of the
overall process (Table 2) [11,51].
Comparisons were also performed to between HaloCHIP-
chip and previously published CREB ChIP-chip data
(Table 2) [29]. As the CREB ChIP-chip DNA microarray
covered approximately 8,000 fewer number of promoters,
the Top 1% and Top 5% of the list correspond to 182 and
898 promoters [29], respectively, which were then used
for the comparison (Table 2). A slightly lower overlap of
26% and 23.8%, respectively is observed, corresponding
to a 5-fold over-representation for both categories com-
pared to what would be predicted by chance (Table 2).
This is not surprising given the differences between these
experiments including; the cell lines used, method of
amplification for the array, as well as the different array
design and platform [29]. Nevertheless, given these differ-
ences it was very encouraging to see a significant overlap
between these independent results.
Schematic of the HaloCHIP-chip microarray experiment design Figure 3
Schematic of the HaloCHIP-chip microarray experiment design. HaloCHIP DNA (10-50 ng) obtained for both the 
experimental HaloTag-CREB and untransfected control sample was purified and amplified to a concentration of 1-10 μg using 
the whole genome amplification (WGA) method (Sigma) [46]. The HaloTag-CREB amplified sample was labelled with Cy5 
(green) and the untransfected control sample with Cy3 (red), then hybridized to a custom DNA oligo microarray manufac-
tured by Roche NimbleGen. The oligo array was designed to cover on average a 1.8 kb region of 27,661 human promoter 
regions that contain 33,255 TSS predicted by SwitchGear Genomics. To obtain coverage of each promoter, an average of four-
teen 50mer single stranded DNA probes, shown in purple, per promoter were used, with an average spacing of 131 bp per 
probe.
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Table 1: CREB HaloCHIP-chip positive and negative predictive 
values.
Positive category Enriched promoters PPV
Top 1% 12 of 12 100%
Top 5% 11 of 12 92%
Top 10% 6 of 12 50%
Negative category Enriched promoters NPV
Bottom 50% 2 of 26 94.50%
Twelve promoters each from the Top 1%, Top 5%, and Top 10% 
categories of the HaloCHIP-chip data were chosen to determine the 
positive predictive value and 36 promoters were chosen from the 
Bottom 50% of the list for determination of the negative predictive 
value. SYBR green qPCR was used to determine the presence of these 
promoters in triplicates samples of HT-CREB experimental and 
untransfected control HaloCHIP DNA and promoters were 
considered enriched if having a signal:background ratio ≥ 2-fold 
between the experimental and control sample. Based upon these 
results, further analysis of the HaloCHIP-chip data was limited to 
promoters identified within the Top 5% of the list.BMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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Further support that the promoters identified by the CREB
HaloCHIP-chip approach are specific for CREB function,
comes from Gene Ontology (GO) analysis of the Top 1%
promoters. GO analysis shows clusters of promoters
found which are involved with histone assembly, chroma-
tin architecture, RNA and DNA metabolism, and nucleic
acid binding pathways, all cellular processes which CREB
has been shown to regulate (Table 3) [23,24].
High resolution mapping of CREB binding sites relative to 
endogenous transcription start sites
Previous genome-wide CREB ChIP-chip studies were con-
ducted on spotted PCR product microarrays [26,29]. Our
use of a custom oligo array that tiles across extended pro-
moter regions (Figure 3) gives us the unique ability to
map CREB binding events at much higher resolution that
in turn allows us to determine the precise location of
binding events relative to transcription start sites. First, we
examined the occurrence and location of putative CREs in
the HaloCHIP dataset as a whole. Enrichment of binding
to both full and half CRE consensus sites within the Top
1% and 5% is observed as compared to the Bottom 90%
of the array list (Table 4). Also, full and half CRE sites are
highly over-represented in the region 100 bp upstream of
the transcription start site (data not shown), consistent
with results seen previously studying the binding pattern
of endogenous CREB [26,29].
The design of the array also allowed for further in-depth
analysis of binding to both unidirectional and bidirec-
tional promoters. A striking observation was that the
majority of CREB-binding events were at bidirectional
promoters, with 60.7% and 53.7% of total promoters
being bidirectional in the Top 1% and 5%, respectively.
Previous work has shown that approximately 10% of the
genes in the genome are divergently transcribed and regu-
lated by a bidirectional promoter (transcription start sites
separated by less than 1000 bp) [49,52,53], suggesting a
strong preference of CREB for binding to divergently tran-
scribed genes. Of the 27,661 promoters covered in this
study, we estimate that 19% have evidence for oppositely
transcribed transcripts initiating in that region. An exam-
ple of CREB binding at a unidirectional promoter, defined
as a promoter associated with a single transcription start
site, is shown in Figure 4a. As expected for both the Halo-
Tag and endogenous CREB, there is enrichment of bind-
Table 2: Comparison of CREB HaloCHIP-chip and CREB ChIP-chip data.
HaloCHIP-chip:ChIP-chip compared Number of Promoters Percentage Overlap Enrichment over Random
Top 1% 96/277 35% 44
Top 5% 616/1383 45% 10
Top 1%* 47/182 26% 5
Top 5%* 212/898 24% 5
HaloCHIP-chip:HaloCHIP-chip compared Number of Promoters Percentage Overlap Enrichment over Random
Top 1% 140/277 51% 65
Top 5% 734/1383 53% 11
ChIP-chip:ChIP-chip compared Number of Promoters Percentage Overlap Enrichment over Random
Top 1% 115/277 42% 53
Top 5% 477/1383 34% 7
The number of promoters found to overlap between the CREB HaloCHIP-chip and standard ChIP-chip experiments were determined for both the 
Top 1% and 5% of each respective list. Also shown is the calculation of the fold enrichment over what is expected for a randomized comparison. 
The first Top 1 and 5% overlap is between CREB HaloCHIP-chip and ChIP-chip data obtained from the same probes and arrays, therefore the 
number of promoters, 277 and 1383 respectively, used for comparison is the same between the two lists. The (*) indicates the comparison of the 
HaloCHIP-chip array data to previously published Top 1 and 5% CREB ChIP-chip data [29]. The Top 1 and 5% CREB ChIP-chip data correspond to 
182 and 898 promoters respectively, and it was these which were used for the comparison to the Top 1 and 5% of the HaloCHIP-chip array data. 
Calculated in a similar fashion is the percentage overlap and enrichment over random between HaloCHIP-chip biological replicate sets or ChIP-chip 
biological replicate data sets.
Table 3: Gene Ontology analysis of CREB HaloCHIP-chip 
promoters.
Cellular Functions Number of Promoters p-value
Histone Assembly 12 of 65 1.26E-06
Chromatin architecture 20 of 261 7.63E-07
Ribonucleic Complexes 26 of 392 7.06E-07
RNA processing 26 of 395 8.01E-07
DNA metabolism 38 of 638 2.93E-08
Nucleic acid binding 110 of 2764 2.19E-09
The Top 1% of the CREB HaloCHIP-chip promoters (277) was 
analyzed using Gene Ontology (GO) and the different categories in 
terms of cellular function of promoters within the Top1%. Also 
shown is the number of CREB HaloCHIP-chip promoters found as 
compared to the number of known human promoters within each 
category and the corresponding p-value calculated by GO.BMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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ing directly upstream of the transcription start site around
the location of a putative CRE site (Figure 4a), and for our
subset analyzed, this pattern of binding was observed
greater than 60% of the time. Analysis of binding within
bidirectional promoters revealed interesting binding pat-
terns for CREB. As shown in Figure 4b, two distinct peaks
of high enrichment are observed just downstream of the
transcription start sites of both genes within a bidirec-
tional promoter, while no enrichment is observed in the
intergenic space between the transcription start sites. As
this is observed for both the HaloTag-CREB fusion protein
as well as the endogenous CREB protein, it does not
appear to be an artefact of either the HaloCHIP or ChIP
methodology. It was also surprising to see that highest
enrichment was not localized at the location of putative
CRE sites in bidirectional promoters, suggesting CREB is
either bound directly elsewhere on DNA or crosslinking to
complexes not bound to CRE consensus sites (Figure 4b).
CREB high-throughput reporter assay analysis
The combination of the CREB genome-wide binding
events identified in this study along with those reported
previously confirm CREB binding events, however do not
predict the transcriptional regulation of its target genes.
Furthermore, CREB binding was measured in a limited set
of conditions (with and without forskolin stimulation),
and it is known that the CREB pathway is activated by a
wide variety of cellular and environmental stimuli
[23,24]. To further characterize the CREB binding events,
we assembled a collection of cloned human promoters (1
kb on average) in a luciferase reporter vector that repre-
sented a subset (235) of known CREB targets previously
identified [26,27,29]. As predicted from the earlier over-
lap calculations with the CREB ChIP-chip data (Table 2)
approximately 35% of these promoters (84) were identi-
fied in the Top 5% of the HaloCHIP-chip array data. As a
control, 12 random promoters that were not targets of
CREB were also fused to luciferase reporters (Figure 5a).
Utilizing our high-throughput reporter assay platform, we
measured the activity of each of these fragments in HeLa
cells in triplicate in 5 different conditions: no treatment,
forskolin (FSK) stimulation, phorbol 12-myristate-13-
acetate (PMA) stimulation, and co-transfection with a
TORC1 expression construct with and without FSK stimu-
lation (Figure 5a). We considered a promoter induced if
the absolute activity was significantly above background,
passed a T-test at p < 0.05, and had a magnitude of change
greater than 2-fold.
The promoter macroarray results are summarized in Fig-
ure 5b, and the percentage of the total CREB promoters
tested (235), as well as the HaloCHIP subset (84), that
were induced in the different conditions were determined
(Table 5). For both the CREB set and the HaloCHIP sub-
set, only ~10% were induced by FSK treatment alone (Fig-
ure 5b, Table 5). This is not surprising since it is known
that many other factors are necessary for the transcrip-
tional activation of CREB-bound promoters and both our
binding data and previously reported data did not show
an appreciable difference in DNA binding between +/-
FSK treatment [23,29,35]. Indeed, the TORC1 co-transfec-
tions induced more than 50% of the constructs (Table 5)
and also conferred the largest fold-changes in activity (Fig-
ure 5b) highlighting the importance of co-factors in the
transcriptional activation of CREB-bound promoters
[32,34]. Similar trends were observed between the overall
CREB set of promoters as compared to the HaloCHIP sub-
set, indicating those identified by HaloCHIP respond sim-
ilarly to CREB-specific stimuli (Table 5). The 12 random
promoters from the human genome do not show induced
activity in any of the conditions tested, indicating that the
false positive rate of the reporter assay for CREB activity is
very low (Figure 5b).
Given the interesting CREB binding patterns at bidirec-
tional promoters (Figure 4b), we looked specifically at the
promoter activities of bidirectional promoters in our
reporter assay dataset. There were a total of 7 bidirectional
gene pairs for which we collected promoter activity data
for each direction. The majority of the pairs showed very
low activity in both directions in the untreated cells sug-
gesting that CREB-bound bidirectional promoters are not
transcriptionally active in an un-induced state. Two of the
7 bidirectional gene pairs, which regulate two pairs of his-
tone genes, had constitutively high promoter activities in
both directions, irrespective of stimulation conditions.
The most interesting example was seen for two of the bidi-
rectional promoter pairs, depicted in Figure 6a, b. For
these bidirectional promoters, no induction was observed
with either FSK or PMA, but in the presence of TORC1,
promoter activity in one direction was significantly up-
regulated while promoter activity was repressed in the
other direction (Figure 6b). CREB enrichment at the
MRPS18B promoter was observed at CRE sites just
upstream of the TSS, while enrichment to the PP1R10 pro-
Table 4: Match of full and half CRE consensus sites in CREB 
HaloCHIP-chip data.
Categories % with Full CRE site % with Half CRE Site
Top 1% 22% 89%
Top 5% 12% 86%
Bottom 90% 3% 57%
CREB HaloCHIP-chip promoters from the Top 1%, Top 5%, and 
Bottom 90% categories were analyzed for the presence of the full 
CRE or half CRE consensus site and number of promoters containing 
these sequences are depicted. A full CRE site was defined as a perfect 
match to the consensus TGACGTCA. A half CRE site was defined as 
a perfect match to the consensus TGACG or CGTCA.BMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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High-resolution analysis of CREB binding at uni-directional and bi-directional promoters Figure 4
High-resolution analysis of CREB binding at uni-directional and bi-directional promoters. Depicted are CREB 
binding data from two representative promoter regions, the length (bp) of each is indicated above the graph. The log2 ratio for 
each probe spanning the promoter region was determined for the CREB ChIP-chip (plotted in red) or HaloCHIP-chip (plotted 
in blue) data. Positions of transcription start sites (TSS) are shown with arrows indicating the direction of transcription with 
length of exons in blocks and introns drawn as lines. Positions of full and half CRE sites relative to the location within the pro-
moter region are indicated below by blue dots. A. Example of CREB binding to a unidirectional promoter, ALS2, where peak 
binding is observed upstream of the TSS and localized to the CRE consensus sites. B. Example of CREB binding to a bidirec-
tional promoter, METTL4 and NDC80, where peak enrichment is located downstream of the TSSs, but the peak enrichment 
does not localize to CRE consensus sites.
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moter was downstream the TSS and not associated with a
CRE site (Figure 6a). Interestingly, only the MRPS18B pro-
moter shows transcriptional activation in the reporter
assay, while the PPP1R10 promoter is significantly
repressed in the presence of TORC1 and FSK (Figure 6b).
These results suggest that TORC1 plays an important role
at some promoters in determining the direction of tran-
scriptional activation.
Discussion
We applied here two technologies, HaloCHIP and high-
throughput promoter assays, to study and more fully char-
acterize the CREB transcription pathway than previously
done. The HaloCHIP method (Figure 1) offers an alterna-
tive approach for the capture of intracellular DNA-protein
complexes and was developed to address the challenges of
antibodies required for the existing ChIP method. The use
of a robust protein tag eliminates the need for a qualified
antibody and enables researchers to study highly similar
paralogs, different isoforms, or point mutants of a tran-
scription factor that may not be distinguishable by an
antibody. Also, due to rapid and covalent binding kinetics
HaloTag with its ligands, protein complexes can be cap-
tured efficiently from dilute solutions without concern of
loss due to diffusion off the resin, allowing for the use of
a much smaller number of cells (2-4 × 105) per HaloCHIP
experiment as compared to the standard ChIP experiment
(~1 × 107) [4,10]. As with the use of any protein fusion tag
for ChIP or HaloCHIP experiments there are concerns as
to potential alteration of DNA binding due to interference
by the fusion tag or changes in expression level. The CREB
HaloCHIP-chip results show that binding to DNA on a
genomic-scale was specific for the CREB protein and had
a significant degree of overlap with conventional CREB
ChIP-chip data, suggesting the HaloTag-CREB fusion pro-
tein is binding to DNA similarly to the endogenous CREB
protein.
In addition to identification of new CREB-bound promot-
ers with these array studies, we extended our studies of the
CREB pathway by measuring the functional activity of
over 200 CREB-target promoters [26,27,29] in a high-
throughput reporter assay experiment (Figure 6a). Many
diverse responses are regulated through the CREB path-
way and unique subsets of CREB-bound genes may be
transcriptionally activated and responsive to particular
stimuli. The high-throughput reporter assays of CREB-
bound promoters gives the ability to stratify CREB bind-
ing events based on the transcriptional activity of the frag-
ments of DNA to which they bind. Analysis of the CREB
pathway using the functional promoter macroarrays
revealed only a small percentage of promoters were
responsive to FSK, correlating well with the HaloCHIP-
chip data showing minimal changes in binding between
untreated and FSK treated cells. Interestingly, a much
larger percentage of promoters were responsive to PMA,
and an even greater percentage to the TORC proteins.
These functional results provide further support for the
idea that co-factors are a crucial part of the CREB signaling
pathway and while reporter assays lack the full chromatin
context of the genome, by using extended promoters
High-throughput reporter assays of CREB-bound promoters Figure 5
High-throughput reporter assays of CREB-bound 
promoters. A. Experimental design of high-throughput 
reporter assays. A schematic showing the high-throughput 
reporter assay experimental design. Promoters are fused to 
luciferase, transfected in a desired cell line, and stimulated 
under different conditions. Luciferase activity is measure 
from uninduced and induced samples and the log2 ratio of 
these differences is calculated. B. Heatmap of inducible pro-
moter activity. A total of 235 promoters, chosen from CREB 
ChIP-chip and HaloCHIP-chip data, along with twelve nega-
tive control promoters were fused to the luciferase gene, 
transfected into HeLa cells, and treated with stimulants; for-
skolin (FSK), PMA, or co-transfected with a transcriptional 
co-activator, TORC1 +/- FSK. Each box represents the log2 
ratio of induced/untreated for each promoter in each condi-
tion where the intensity of red is proportional to the strong-
est induction and the intensity of blue is proportional to the 
strongest repression. The presence of TORC1 by co-trans-
fection shows the highest number of promoters induced to 
the highest degree. The box of 12 control promoters at the 
bottom of the panel are random promoters from the 
genome and show very little inducible activity in any of the 
conditions tested.BMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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regions that are 1 kb in length, we were able to observe
transcriptional effects by co-factors, which may interact
with proximal sites. In order to analyze CREB-enriched
sites at a much higher resolution than was previously per-
formed, custom oligo microarrays were used. This
detailed analysis provided interesting and novel insight
into the localization of CREB at the promoters of genes. A
simple assumption is that the experimental enrichment
for CREB binding would be coincident with the location
of the CRE. Indeed this was observed for the majority of
unidirectional promoters (Figure 4a). However, a dis-
tinctly different pattern is observed for a large fraction of
bidirectional promoters, where the peaks of highest
enrichment are seen downstream of the closest TSS, often
not coinciding with the location of CREs (Figure 4b). This
pattern was seen consistently for many bidirectional pro-
moters, in both HaloCHIP-chip and ChIP-chip data sets,
indicating this is not a phenomenon associated with a
particular method.
These particular binding results suggest a number of inter-
esting scenarios for which additional experiments will be
needed. It may be the case that there is a secondary struc-
ture of the CREB-DNA complex at bidirectional promot-
ers where the peaks of enrichment reflect the higher order
crosslinked structure rather than the true localization of
the CREB protein on the linear strand of genomic DNA.
An alternative explanation is that CREB may be a part of a
paused transcription initiation complex. In this scenario,
CREB could initially bind upstream of the TSS in the bidi-
rectional promoters, form its known interactions with the
RNA PolII complex, move after initiation with the com-
plex, and then pause at particular sites downstream of the
TSS. Recent work has shown that a paused transcriptional
complex containing transcriptional regulators are more
abundant than previously thought [54-56], and this
explanation would produce the enrichment pattern that
we observe for CREB at bidirectional promoters (Figure
4b, 6b).
Results from the promoter reporter assays for bidirec-
tional promoters are also consistent with this scenario,
since a paused transcriptional machinery would likely
result in lower reporter activity as was seen for the major-
ity of bidirectional promoters tested. Perhaps most inter-
esting is the functional behaviour of a subset of the
bidirectional promoters in the presence of TORC1. In 2
out of 7 cases tested, the activity of a bidirectional pro-
moter was strongly induced in one direction and strongly
repressed in the opposite direction in the presence of
TORC1. The strongly repressed promoters show CREB
binding which is downstream the TSS, while the strongly
induced promoters show expected upstream promoter
binding. Also, the ability of the TORC1 protein to differ-
entially regulate promoter activity, suggests that CREB co-
factors may also help to regulate the directionality of tran-
scription. This is particularly relevant for the CREB tran-
scription factor, since over 50% of CREB binding sites are
located in bidirectional promoters as we have reported for
the first time.
Conclusion
This broad survey of the transcriptional activity of CREB-
bound promoters provides a valuable layer of functional
data for the CREB protein. Future efforts to compare the
activity of these promoters in many more conditions will
help to further understand CREB signaling and muta-
tional analysis of the bidirectional class of CREB-bound
promoters will help to dissect the mechanism of bidirec-
tional gene regulation. The use of the new technologies
presented here however is not limited to the study of the
CREB pathway, rather can be generalized to study any
transcriptional pathway. The HaloCHIP method, like the
standard ChIP process, can be used to study DNA binding
both on a small scale, as well as genome-wide scale, how-
ever follow up studies characterizing the functional conse-
quences of these binding events have lagged much further
behind. By expanding the use of high-throughput reporter
assays, we hope to advance our understanding of these
functional consequences. This comprehensive compari-
son reveals the challenges and potential pitfalls of extrap-
olating binding events to transcriptional activation and
shows the need for both approaches, as well as other
experiments to truly characterize transcriptional activity.
Table 5: Percentage of promoters activated in various conditions in functional macroarrays.
Total CREB Set Tested (235) HaloCHIP Subset (84)
Stimulants % Induced % Induced
FSK 9.8% 9.5%
PMA 31.9% 26.2%
TORC1 60.4% 50.0%
TORC1 + FSK 65.1% 54.8%
ANY 76.2% 66.7%
Table 5 shows the percentage of promoters activated in each condition from both the total CREB set (235) or a subset of the total CREB set (84), 
termed the HaloCHIP subset, that was found in the Top 5% of the CREB HaloCHIP-chip array list. The HaloCHIP-chip data follows the same trend 
of response to each stimulus as the larger CREB set.BMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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CREB binding and promoter activity at a bidirectional promoter showing opposite induction patterns in the presence of  TORC1 Figure 6
CREB binding and promoter activity at a bidirectional promoter showing opposite induction patterns in the 
presence of TORC1. A. CREB binding to PPP1R10/MRPS18B bidirectional promoter. Identical to Figure 4, the log2 ratio for 
each probe spanning this bidirectional promoter was determined for the CREB ChIP-chip (plotted in red) or HaloCHIP-chip 
(plotted in blue) data. Spacing between probes is approximately 131 bp. Positions of transcription start sites (TSS) are shown 
with arrows indicating the direction of transcription with lengths of exons in blocks and introns drawn as lines. Positions of full 
CRE sites are indicated below by blue dots. Also shown is the region of each cloned promoter fragments, indicated by the 
green and blue arrows, used in the luciferase assay shown below in panel B. The arrows indicate the direction in which the 
cloned fragments were tested in the luciferase assay. B. The log2 ratio of treated/untreated luciferase activity is plotted for 
each promoter fragment in each condition indicated. The MRPS18B promoter (in green) shows significant inducible activity in 
the presence of TORC1 with and without FSK, while the PPP1R10 promoter (in blue) shows significant repression in the pres-
ence of TORC1 with and without FSK.
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Methods
Cloning, cell lines, and transfections of HaloTag vectors
Full-length human CREB1-α and -Δ cDNAs were obtained
from OriGene, [NCBI:NM_134442.2 and
NCBI:NM_004379.2], respectively. All CREB variants
were subcloned into the pFN21A HaloTag CMV Flexi Vec-
tor (Promega) using SgfI and Pme, generating N-terminal
HaloTag fusion constructs for each. HeLa cells (ATCC
#CCL-2) were maintained in DMEM supplemented with
10%FBS at 37°C in an atmosphere of 5% CO2. Cells were
transfected using Lipofectamine LTX transfection reagent
(Invitrogen) according manufacturer's protocols.
HaloCHIP Protocol and Whole Genome Amplification
A detailed version of the HaloCHIP protocol can be found
at: http://www.promega.com/tbs/tm075/tm075.html
For these experiments, HeLa cells (2-4 × 105) were plated
in a single well of a standard 6-well plate. After reaching
70-80% confluency, typically 18-24 hours later, cells were
transfected with the HaloTag-CREB fusion constructs
(experimental sample) or left untransfected (control sam-
ple). Twenty four hours post-transfection, cells were
crosslinked with formaldehyde (Sigma) at a final concen-
tration of 0.75% for 10 minutes at 22°, quenched with
0.125 M glycine for 10 min. and processed using the
HaloCHIP kit (Promega). For experiments involving For-
skolin, cells were treated with 10 μM Forskolin for 45
minutes at 37°C prior to crosslinking. Isolated DNA was
further purified using a PCR Clean-up kit (Qiagen), and
eluted 2 × 50 μl with nuclease-free water, yielding a final
volume of 100 μl. To prepare sufficient HaloCHIP DNA
for downstream amplification steps required for microar-
rays, an entire 6-well plate was transfected and processed
through the HaloCHIP method as recommended. The iso-
lated DNA was pooled before final purification on the
PCR clean-up columns and lyophilized to a final volume
of 12 μl. The concentrated HaloCHIP DNA was then
amplified to 2-10 μg using the Whole Genome Amplifica-
tion kit (Sigma) following the recommended adaptation
for ChIP samples [46].
ChIP Protocol
HeLa cells (4 × 106) were plated in several 150 mm plates
and grown at 37°C to 80-90% confluency. Cells were
treated with 10 uM forskolin for 45 minutes at 37°.
crosslinked with formaldehyde (Sigma) at a final concen-
tration of 1.0% for 10 minutes at 22°, quenched with
0.125 M glycine for 10 min. and processed using the ChIP
Assay Kit (USB). Chromatin was sheared by sonication
using a Misonix MicroTip Probe 418, output of 5.5, with
a program of 15 cycles of 5 seconds on and 25 seconds off
on ice. Co-immunoprecipitation was performed using 1
μg of anti-CREB1 antibody (Millipore #06-863) for the
experimental sample and 1 μg of anti-IgG antibody
(Sigma) for the control sample with incubation at 4°C for
15 hours. Isolated DNA was further purified using a PCR
Clean-up kit (Qiagen), processed, and amplified using
WGA identical as the HaloCHIP samples.
Quantitative PCR and primers
HaloCHIP DNA was analyzed using either Plexor
(Promega) or SYBR green (Applied Biosystems) qPCR
according to their respective manufacturer's recommenda-
tions. Plexor primers were supplied from Biosearch Tech-
nologies and SYBR green primers were from IDT DNA.
The following sequences were used for amplification: Fos
forward 5'-GTCTTGGCTTCTCAGATGCTCG-3', reverse 5'-
GTTGAGCCCGTGACGTTTACA-3',  Jun  forward 5'-GAG
AAAGAAGGGCCCGACTGT-3', reverse 5'-GGAGACTC-
CACCCTAGAAGATTCT-3', p27 forward 5'-GGGAGGCT-
GACGAAGAAGAAAAT-3', reverse 5'-CAACCAATGGAT
CTCCTCCTCTG-3', C1 forward 5'-CTGGTCTCACCTAC-
CTTCCTGT-3', reverse 5'-ATCCATGAACTCCAGGAGCTC
A-3' C2 forward 5'-TCTGTTGCCTATTGACCAGAACATG-
3', reverse 5'-AGGAGCTGTAGGCTGAGTCAC-3', C3 for-
ward 5'-CTGCTTCTTAACAGCTTAATTCGGAAGA-3',
reverse 5'-ATGAGCAAAGATAGCTCAGGGAG-3'. Primers
sequences used for PPV and NPV qPCR validation along
with their corresponding amplified promoter can be
found in supplemental materials: http://www.switch
geargenomics.com/creb_supp_data/
Oligo array design and analysis
A custom oligo array was designed to cover a genome-
wide set of human promoter regions predicted by Switch-
Gear Genomics (more detail can be found at http://
www.switchgeargenomics.com). The oligo array com-
posed of approximately ~385,000 50mer probes was
manufactured by Roche-NimbleGen Systems. The ampli-
fied enriched samples described above were shipped to
Roche-NimbleGen to be hybridized according to their
standard service protocol. The raw data from the arrays
were analyzed as follows; the log2 ratio (enriched-cy5/
total input-cy3) was calculated for each probe and data
were then smoothed by averaging across a sliding window
of 3 neighbouring probes shifting 1 probe at a time, min-
imizing noise from single probes. The median and stand-
ard deviation were calculated from the smoothed ratios
for each sample. The median was subtracted from each
ratio and divided by the standard deviation to center and
normalize the data from each array. To summarize the
enrichment for an entire promoter, the top 4 probe values
were averaged for a given promoter region to approximate
the 75th percentile value. The raw data, normalized data,
and collapsed data for each array are available as supple-
mental at the following site: http://www.switchgearge
nomics.com/creb_supp_data/. All microarray probes and
data discussed in this publication have been deposited in
NCBI's Gene Expression Omnibus[57] and are accessibleBMC Genomics 2009, 10:497 http://www.biomedcentral.com/1471-2164/10/497
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through GEO Series accession number GSE18347 http://
www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE18347.
Gene Ontology (GO) analysis
The Top 1% of the CREB HaloCHIP-chip promoters, 277
in total, were deposited and analyzed using Gene Ontol-
ogy (GO) http://www.geneontology.org/ and AmiGO as
the search engine. GO categorized each promoter with
respect to protein function, showed the number of pro-
moters within each category, and reported a correspond-
ing p-value based upon the calculations.
High-throughput reporter assays and analysis
The promoter reporter assays used 235 promoter-reporter
vectors (utilizing the luc2P  reporter cassette from
Promega) containing ~1 kb promoter fragments from
known CREB-bound genes. These cloned promoters were
selected from SwitchGear Genomic's genome-wide pro-
moter clone collection (details on this panel of reporter
constructs can be found at http://www.switchdb.com/
pathways/id_46/). A panel of promoter controls was also
used to normalize signals between plates and replicates.
The 32 plate normalization controls, include ~1 kb frag-
ments representing constitutively active human promoter
fragments and random regions from the genome. The pro-
moter reporter assay experiments were all conducted in
384-well format. A detailed protocol can be found at:
http://www.switchgeargenomics.com/creb_supp_data/.
Transfection complexes were formed by incubating 50 ng
of each individual promoter construct with 0.3 μL of
Fugene 6 transfection reagent and Opti-MEM media in a
total volume of 3 μL and incubated for 30 minutes. The
co-transfection of the TORC1 expression construct was set
up the same as the standard transfection reaction, but
with the inclusion of 25 ng of TORC1 expression plasmid
per reaction (TORC1 expression construct was provided
by the Montminy lab). Transfection complexes were
mixed with resuspended HeLa cells such that 4,000 HeLa
cells were seeded in a volume of 50 μL in each well of a
384-well white tissue culture treated plate. Fifteen repli-
cate wells of each promoter construct were performed rep-
resenting triplicate assays in 5 different conditions: 1) no
treatment, 2) PMA, 3) Forskolin, 4) TORC1, and 5)
TORC1 + FSK.
After seeding and transfection, cells were incubated for 24
hours before inductions. Inductions were conducted for
each plate by removing the old media and replacing with
new media depending on the condition. For the untreated
cells, fresh media was applied to each well. For the PMA
induction, fresh media with 100 nM PMA was added to
each well. For the forskolin induction, fresh media with
20 μM FSK was added to each well. Cells were kept in their
respective induction condition for 4 hours and then fro-
zen overnight at -80 degrees.
To read luminescent activity plates were thawed for 45
minutes at room temperature. Then 50 μL of Steady-Glo
reagent (Promega #E2520) was added and incubated for
30 minutes at room temperature. Then luminescence was
read for 2 seconds per well on a 384-well compatible plate
luminometer (Molecular Devices LMax384).
The raw luminescent reads from each well were normal-
ized as follows. Each 384 well plate contained 32 control
wells that were comprised of 16 positive control promot-
ers and 16 random genomic fragments that serve as back-
ground signal controls. These plate controls were used to
normalize the per well values between plates within a con-
dition. The average of the 3 replicates was taken, and the
ratio of induced/untreated was calculated from the aver-
ages of the treated values and the untreated sample. A t-
test for significance was also calculated between the 3 rep-
licates of the induced and untreated samples. The back-
ground controls were also used to measure whether the
average absolute signals were above background in each
condition (>3 standard deviations from the mean of the
negative controls). For a given promoter to be called
induced or repressed it must pass the following criteria: 1)
At least a 2-fold change (+/-) 2) Pass t-test with signifi-
cance of p < 0.05 3) Must have absolute signals signifi-
cantly above background.
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